Project Grant R01HL173490
Award Date
6/15/24
Completion Date
5/31/29
Dollars Obligated
$1.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
The Project Grant award R01HL173147, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to identify and characterize novel genes that cause primary ciliary dyskinesia (PCD). The $741,404 award will fund a comprehensive analysis of PCD-linked genes using the Xenopus embryonic skin ciliated epithelium as a model system. The research aims to develop quantifiable assays to assess multiple aspects of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $717,236 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Iowa to study the role of neuronal primary cilia in hypertension, autonomic dysfunction, and body fluid imbalance. The key products and services to be delivered under this 4-year grant include: Evaluating how conditional ablation of cilia in the supraoptic nucleus affects blood pressure, drinking, urine volume, sodium concentration, plasma...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $762,867 to The Johns Hopkins University to investigate the role of the protein cofilin-1 in regulating mitochondrial function and repair mechanisms in airway epithelial cells. The research aims to determine how the loss of cofilin-1 impacts mitochondrial dynamics, mitophagy, and biogenesis, as well as its effects on airway epithelial...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $583,233 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to The Washington University in St. Louis. The grant, which runs from April 1, 2025 to January 31, 2029, supports research to investigate the molecular mechanisms and mediators of detrimental kidney-lung interactions that contribute to respiratory failure in patients with multiorgan failure. The project aims to: 1) Determine which...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $605,678 project grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to the University of South Alabama. The award will fund a 4-year research project from May 2025 to February 2029 that aims to explore a novel "BRACR" (Base Oxidation and Repair Activated Chromatin Restructuring) pathway as a regulator of the genome-wide transcriptional response to hypoxia in lung disease. The research will...
This $108,405 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of primary cilia in regulating vascular stability during embryonic development. The key objectives are to: 1) assess how endothelial cell primary cilia respond to changes in hemodynamic forces, 2) determine the influence of primary cilia on mural cell recruitment, differentiation,...
This $596,179 five-year Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a research program at Baylor College of Medicine focused on determining the roles of macropinocytosis and its molecular mechanisms in pulmonary fibrosis. The project aims to assess whether macropinocytosis deficiency can attenuate fibrosis in animal...
The National Heart, Lung, and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), awarded a $242,310 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). This grant, effective July 1, 2024 through November 30, 2026, will support UCSF's research to adapt cell-based therapies for the treatment of pulmonary fibrosis. As a leading academic medical research institution, UCSF...
This federal Project Grant award of $701,440.00 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the function of the RUVBL1-RUVBL2 proteins in the assembly of dynein arms, which power the rhythmic beating of motile cilia. The research aims to define the mechanism of RUVBL1-RUVBL2 foci formation and to systematically characterize the components and biochemical/functional relationships...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $802,500 Cooperative Agreement grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Childrens Hospital Medical Center in Cincinnati, Ohio. The grant, with a performance period from September 1, 2024 to August 31, 2029, will support the development of a 3D AI-powered map of genetic factors underlying normal and aberrant childhood lung development, including in the context of childhood interstitial lung...